Teva and Sanofi report Phase 2b data for duvakitug in IBDnews2024-12-17T12:30:25+00:00December 17th, 2024|Endpoints News|
Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosionnews2024-12-17T11:47:19+00:00December 17th, 2024|Endpoints News|
Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye diseasenews2024-12-16T20:14:30+00:00December 16th, 2024|Endpoints News|
Edgewise shares spike on Phase 2 success for muscular dystrophy drugnews2024-12-16T16:34:57+00:00December 16th, 2024|Endpoints News|
PureTech declares mid-stage trial win for pulmonary fibrosis drugnews2024-12-16T16:14:06+00:00December 16th, 2024|Endpoints News|
Biohaven’s protein degrader cuts antibodies by 60%news2024-12-16T16:03:28+00:00December 16th, 2024|Endpoints News|
Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio reviewnews2024-12-16T11:45:07+00:00December 16th, 2024|Endpoints News|
Roche terminates a Phase 3 Spark gene therapy in hemophilia Anews2024-12-16T11:20:45+00:00December 16th, 2024|Endpoints News|
Bicycle Therapeutics stock sinks following cancer datanews2024-12-13T19:49:09+00:00December 13th, 2024|Endpoints News|
Boundless shares dip as it nixes cancer asset, reshuffles execsnews2024-12-13T16:11:04+00:00December 13th, 2024|Endpoints News|
